Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02416973 · ClinicalTrials.gov registry record · NA
Study of PEMF (Pulsed Electromagnetic Field) Therapy in the Treatment of Persistent Post-Operative Pain Following Lumbar Surgery
A NA study of Lumbar Surgery, sponsored by Regenesis Biomedical.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
- 8
- Study locations
NCT02416973: Completed NA study of Lumbar Surgery, sponsored by Regenesis Biomedical.
NCT02416973 is a NA study of Lumbar Surgery that has completed, run by Regenesis Biomedical. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02416973, a NA study of Lumbar Surgery, has completed, sponsored by Regenesis Biomedical.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
- 8
- Study locations
Study Summary
To demonstrate the analgesic effectiveness of 2 modalities of PEMF treatment compared to sham treatment in patients with persistent pain following lumbar surgery when treatment is administered twice daily over a 60 day period.
Primary Outcome
Numerical Pain Rating Scale (NPRS) was used to score pain at Baseline and at End of Treatment. The Percent change (difference) from Baseline to End of Treatment was calculated. The NPRS is an 11-point scale ranging from scores of 0 (no pain) to 10 (worst pain imaginable).
Conditions Studied
Interventions
- DEVICE Provant
Study Locations (8)
Alabama
- AOC-Research - Birmingham
Arizona
- Hope Research - Phoenix
Idaho
- Injury Care Research - Boise
Illinois
- Rockford Orthopedic - Rockford
Nevada
- Hope Research_Las Vegas - Las Vegas
North Carolina
- Tarheel Clinical Research - Raliegh
South Carolina
- Upstate Clinical - Spartanburg
Virginia
- Danville Orthopedic - Danville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-08 |
| Phase | NA |
What the finished NCT02416973 record still lists
NCT02416973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Lumbar Surgery appearing as the primary indexed condition, and to 1 intervention - of which Provant is the first listed.
NCT02416973 lists 8 locations in 8 states (Alabama, Arizona, Idaho).
Frequently Asked Questions
What is clinical trial NCT02416973 about?
NCT02416973 is a clinical study titled "Study of PEMF (Pulsed Electromagnetic Field) Therapy in the Treatment of Persistent Post-Operative Pain Following Lumbar Surgery". To demonstrate the analgesic effectiveness of 2 modalities of PEMF treatment compared to sham treatment in patients with persistent pain following lumbar surgery when treatment is administered twice daily over a 60 day period.
What is the current status of trial NCT02416973?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2015-03. Estimated completion is 2016-08.
What conditions does trial NCT02416973 study?
This clinical trial studies the following conditions: Lumbar Surgery.
What interventions are being tested in trial NCT02416973?
The interventions under investigation include: Provant (DEVICE).
Who is sponsoring clinical trial NCT02416973?
This trial is sponsored by Regenesis Biomedical, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02416973 being conducted?
This trial has 8 study locations across Alabama, Arizona, Idaho, Illinois, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02416973's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia